297 related articles for article (PubMed ID: 30051267)
1. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L.
Hobbins A; Barry L; Kelleher D; Shah K; Devlin N; Goni JMR; O'Neill C
Pharmacoeconomics; 2018 Nov; 36(11):1345-1353. PubMed ID: 30051267
[TBL] [Abstract][Full Text] [Related]
2. Test-Retest Reliability of EQ-5D-5L Valuation Techniques: The Composite Time Trade-Off and Discrete Choice Experiments.
Purba FD; Hunfeld JAM; Timman R; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Passchier J; Busschbach JJV
Value Health; 2018 Oct; 21(10):1243-1249. PubMed ID: 30314626
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
[TBL] [Abstract][Full Text] [Related]
4. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
Golicki D; Jakubczyk M; Graczyk K; Niewada M
Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
[TBL] [Abstract][Full Text] [Related]
5. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
[TBL] [Abstract][Full Text] [Related]
6. Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set.
Jyani G; Sharma A; Prinja S; Kar SS; Trivedi M; Patro BK; Goyal A; Purba FD; Finch AP; Rajsekar K; Raman S; Stolk E; Kaur M
Value Health; 2022 Jul; 25(7):1218-1226. PubMed ID: 35779943
[TBL] [Abstract][Full Text] [Related]
7. Valuing Health Using Time Trade-Off and Discrete Choice Experiment Methods: Does Dimension Order Impact on Health State Values?
Mulhern B; Shah K; Janssen MF; Longworth L; Ibbotson R
Value Health; 2016; 19(2):210-7. PubMed ID: 27021755
[TBL] [Abstract][Full Text] [Related]
8. The Indonesian EQ-5D-5L Value Set.
Purba FD; Hunfeld JAM; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Ramos-Goñi JM; Passchier J; Busschbach JJV
Pharmacoeconomics; 2017 Nov; 35(11):1153-1165. PubMed ID: 28695543
[TBL] [Abstract][Full Text] [Related]
9. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
[TBL] [Abstract][Full Text] [Related]
10. An EQ-5D-5L Value Set for Vietnam.
Mai VQ; Sun S; Minh HV; Luo N; Giang KB; Lindholm L; Sahlen KG
Qual Life Res; 2020 Jul; 29(7):1923-1933. PubMed ID: 32221805
[TBL] [Abstract][Full Text] [Related]
11. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
[TBL] [Abstract][Full Text] [Related]
12. Valuation of EQ-5D-5L health states: a comparison of seven Asian populations.
Wang P; Liu GG; Jo MW; Purba FD; Yang Z; Gandhi M; Pattanaphesaj J; Ahn J; Wong EL; Shafie AA; Busschbach JJ; Luo N
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):445-451. PubMed ID: 30523723
[No Abstract] [Full Text] [Related]
13. The EQ-5D-5L Valuation study in Thailand.
Pattanaphesaj J; Thavorncharoensap M; Ramos-Goñi JM; Tongsiri S; Ingsrisawang L; Teerawattananon Y
Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):551-558. PubMed ID: 29958008
[TBL] [Abstract][Full Text] [Related]
14. Valuing Health State: An EQ-5D-5L Value Set for Ethiopians.
Welie AG; Gebretekle GB; Stolk E; Mukuria C; Krahn MD; Enquoselassie F; Fenta TG
Value Health Reg Issues; 2020 Sep; 22():7-14. PubMed ID: 31683254
[TBL] [Abstract][Full Text] [Related]
15. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.
Fitriana TS; Roudijk B; Purba FD; Busschbach JJV; Stolk E
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):157-167. PubMed ID: 36348155
[TBL] [Abstract][Full Text] [Related]
16. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
[TBL] [Abstract][Full Text] [Related]
17. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
[TBL] [Abstract][Full Text] [Related]
18. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
Ludwig K; von der Schulenburg JG; Greiner W
Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
[TBL] [Abstract][Full Text] [Related]
19. EQ-5D-5L Valuation for the Malaysian Population.
Shafie AA; Vasan Thakumar A; Lim CJ; Luo N; Rand-Hendriksen K; Md Yusof FA
Pharmacoeconomics; 2019 May; 37(5):715-725. PubMed ID: 30535779
[TBL] [Abstract][Full Text] [Related]
20. Valuation of the EQ-5D-5L in Taiwan.
Lin HW; Li CI; Lin FJ; Chang JY; Gau CS; Luo N; Pickard AS; Ramos Goñi JM; Tang CH; Hsu CN
PLoS One; 2018; 13(12):e0209344. PubMed ID: 30586400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
